Tumor deposits should not be placed in the M category of TNM: A comparative survival analysis using SEER data

IF 4.7 2区 医学 Q1 ONCOLOGY International Journal of Cancer Pub Date : 2024-09-05 DOI:10.1002/ijc.35165
Ayse Selcen Oguz Erdogan, Femke Simmer, Iris D. Nagtegaal
{"title":"Tumor deposits should not be placed in the M category of TNM: A comparative survival analysis using SEER data","authors":"Ayse Selcen Oguz Erdogan,&nbsp;Femke Simmer,&nbsp;Iris D. Nagtegaal","doi":"10.1002/ijc.35165","DOIUrl":null,"url":null,"abstract":"<p>Tumor deposits (TD) are tumor nodules in the lymphatic drainage area of colorectal cancer patients, and they are currently classified in the N category in the TNM classification. However, due to the associated poor prognosis, some small cohort studies suggest that TD belong in the M category. A retrospective study using The Surveillance, Epidemiology, and End Results program (SEER) data was performed in Stages III and IV colon carcinoma (CC) patients to evaluate the prognostic impact of TD. In multivariate analysis, TD have significantly negative effect on survival in both stages (Stage III HR = 1.4 [95% CI 1.4–1.5] and Stage IV HR = 1.3 [95% CI 1.2–1.3]). In Stage III, 5-year overall survival (OS) for patients with TD 49%, whereas it was 64% for patients without TD (<i>p</i> &lt; .001). Additionally, in Stage IV patients without TD, the 5-year OS rates are superior at 21% compared to patients with TD, who show 5-year OS rate of 10% (<i>p</i> &lt; .001). Stage III patients with TD (5-year OS 49%) have a significantly better prognosis compared to Stage IV patients (5-year OS 17%, <i>p</i> &lt; .001). Therefore, despite the previous suggestions, this large scale study (<i>n</i> = 52,332) on outcomes in CC does not support the classification of TD in Stage IV.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":"156 2","pages":"274-279"},"PeriodicalIF":4.7000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ijc.35165","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ijc.35165","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Tumor deposits (TD) are tumor nodules in the lymphatic drainage area of colorectal cancer patients, and they are currently classified in the N category in the TNM classification. However, due to the associated poor prognosis, some small cohort studies suggest that TD belong in the M category. A retrospective study using The Surveillance, Epidemiology, and End Results program (SEER) data was performed in Stages III and IV colon carcinoma (CC) patients to evaluate the prognostic impact of TD. In multivariate analysis, TD have significantly negative effect on survival in both stages (Stage III HR = 1.4 [95% CI 1.4–1.5] and Stage IV HR = 1.3 [95% CI 1.2–1.3]). In Stage III, 5-year overall survival (OS) for patients with TD 49%, whereas it was 64% for patients without TD (p < .001). Additionally, in Stage IV patients without TD, the 5-year OS rates are superior at 21% compared to patients with TD, who show 5-year OS rate of 10% (p < .001). Stage III patients with TD (5-year OS 49%) have a significantly better prognosis compared to Stage IV patients (5-year OS 17%, p < .001). Therefore, despite the previous suggestions, this large scale study (n = 52,332) on outcomes in CC does not support the classification of TD in Stage IV.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肿瘤沉积不应归入 TNM 的 M 类:利用 SEER 数据进行的生存比较分析。
肿瘤沉积(TD)是指结直肠癌患者淋巴引流区的肿瘤结节,目前在 TNM 分类中被归为 N 类。然而,由于其预后较差,一些小型队列研究认为 TD 属于 M 类。一项利用监测、流行病学和最终结果计划(SEER)数据对 III 期和 IV 期结肠癌(CC)患者进行的回顾性研究评估了 TD 对预后的影响。在多变量分析中,TD 对两期患者的生存率均有明显的负面影响(III 期 HR = 1.4 [95% CI 1.4-1.5],IV 期 HR = 1.3 [95% CI 1.2-1.3])。在 III 期,TD 患者的 5 年总生存率(OS)为 49%,而无 TD 患者的 5 年总生存率(OS)为 64%(p
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
13.40
自引率
3.10%
发文量
460
审稿时长
2 months
期刊介绍: The International Journal of Cancer (IJC) is the official journal of the Union for International Cancer Control—UICC; it appears twice a month. IJC invites submission of manuscripts under a broad scope of topics relevant to experimental and clinical cancer research and publishes original Research Articles and Short Reports under the following categories: -Cancer Epidemiology- Cancer Genetics and Epigenetics- Infectious Causes of Cancer- Innovative Tools and Methods- Molecular Cancer Biology- Tumor Immunology and Microenvironment- Tumor Markers and Signatures- Cancer Therapy and Prevention
期刊最新文献
Thoracic radiotherapy synergizes with first-line EGFR-TKIs in advanced EGFR-mutant NSCLC: A dual-center real-world study. Challenges in the future of cancer screening. Efficacy and immunogenic effects of Tumor Treating Fields (TTFields) in preclinical models of pancreatic ductal adenocarcinoma, with and without gemcitabine/nab-paclitaxel. Metabolome analysis identified exogenous cholesterol within lipid rafts that activate the Akt/mTOR signaling pathway in epithelial ovarian cancer. Association of recurrence patterns and outcome with HR and HER2 status in patients with resected brain metastases from breast cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1